IGMS
Price
$1.27
Change
-$0.01 (-0.78%)
Updated
Jul 25 closing price
Capitalization
76.44M
16 days until earnings call
MRSN
Price
$0.31
Change
-$0.01 (-3.12%)
Updated
Jul 25 closing price
Capitalization
959.66M
11 days until earnings call
Interact to see
Advertisement

IGMS vs MRSN

Header iconIGMS vs MRSN Comparison
Open Charts IGMS vs MRSNBanner chart's image
IGM Biosciences
Price$1.27
Change-$0.01 (-0.78%)
Volume$108.76K
Capitalization76.44M
Mersana Therapeutics
Price$0.31
Change-$0.01 (-3.12%)
Volume$5.65M
Capitalization959.66M
IGMS vs MRSN Comparison Chart in %
Loading...
IGMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IGMS vs. MRSN commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IGMS is a Hold and MRSN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (IGMS: $1.27 vs. MRSN: $0.31)
Brand notoriety: IGMS and MRSN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IGMS: 17% vs. MRSN: 184%
Market capitalization -- IGMS: $76.44M vs. MRSN: $959.66M
IGMS [@Biotechnology] is valued at $76.44M. MRSN’s [@Biotechnology] market capitalization is $959.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IGMS’s FA Score shows that 0 FA rating(s) are green whileMRSN’s FA Score has 0 green FA rating(s).

  • IGMS’s FA Score: 0 green, 5 red.
  • MRSN’s FA Score: 0 green, 5 red.
According to our system of comparison, IGMS is a better buy in the long-term than MRSN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IGMS’s TA Score shows that 4 TA indicator(s) are bullish while MRSN’s TA Score has 3 bullish TA indicator(s).

  • IGMS’s TA Score: 4 bullish, 5 bearish.
  • MRSN’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, IGMS is a better buy in the short-term than MRSN.

Price Growth

IGMS (@Biotechnology) experienced а -0.78% price change this week, while MRSN (@Biotechnology) price change was -12.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

IGMS is expected to report earnings on Nov 06, 2025.

MRSN is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRSN($960M) has a higher market cap than IGMS($76.4M). MRSN (-78.462) and IGMS (-79.214) have similar YTD gains . MRSN has higher annual earnings (EBITDA): -68.42M vs. IGMS (-178.4M). IGMS has more cash in the bank: 152M vs. MRSN (102M). MRSN has less debt than IGMS: MRSN (24.6M) vs IGMS (44M). MRSN has higher revenues than IGMS: MRSN (34M) vs IGMS (2.68M).
IGMSMRSNIGMS / MRSN
Capitalization76.4M960M8%
EBITDA-178.4M-68.42M261%
Gain YTD-79.214-78.462101%
P/E RatioN/AN/A-
Revenue2.68M34M8%
Total Cash152M102M149%
Total Debt44M24.6M179%
FUNDAMENTALS RATINGS
IGMS vs MRSN: Fundamental Ratings
IGMS
MRSN
OUTLOOK RATING
1..100
287
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6491
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRSN's Valuation (88) in the Biotechnology industry is in the same range as IGMS (93) in the null industry. This means that MRSN’s stock grew similarly to IGMS’s over the last 12 months.

MRSN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IGMS (100) in the null industry. This means that MRSN’s stock grew similarly to IGMS’s over the last 12 months.

MRSN's SMR Rating (100) in the Biotechnology industry is in the same range as IGMS (100) in the null industry. This means that MRSN’s stock grew similarly to IGMS’s over the last 12 months.

IGMS's Price Growth Rating (64) in the null industry is in the same range as MRSN (91) in the Biotechnology industry. This means that IGMS’s stock grew similarly to MRSN’s over the last 12 months.

IGMS's P/E Growth Rating (100) in the null industry is in the same range as MRSN (100) in the Biotechnology industry. This means that IGMS’s stock grew similarly to MRSN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IGMSMRSN
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 17 days ago
79%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IGMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WIISX14.66N/A
N/A
William Blair International Sm Cap Gr R6
MVEIX11.02N/A
N/A
Monteagle Select Value I
AEURX8.87N/A
N/A
American Century Equity Income R
SCVFX29.71N/A
N/A
Allspring Small Company Value C
MKCPX26.95N/A
N/A
BlackRock Balanced K

IGMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IGMS has been loosely correlated with MRSN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if IGMS jumps, then MRSN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IGMS
1D Price
Change %
IGMS100%
-0.78%
MRSN - IGMS
53%
Loosely correlated
-4.38%
CRNX - IGMS
47%
Loosely correlated
+1.91%
DYN - IGMS
46%
Loosely correlated
+7.68%
MDGL - IGMS
42%
Loosely correlated
-0.26%
APLS - IGMS
40%
Loosely correlated
-2.49%
More